S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
66,000% upside on tiny biotech? (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
66,000% upside on tiny biotech? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
66,000% upside on tiny biotech? (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
66,000% upside on tiny biotech? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
66,000% upside on tiny biotech? (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
66,000% upside on tiny biotech? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
66,000% upside on tiny biotech? (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
66,000% upside on tiny biotech? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
NASDAQ:VAXX

Vaxxinity (VAXX) Stock Forecast, Price & News

$1.99
+0.01 (+0.51%)
(As of 06/8/2023 ET)
Compare
Today's Range
$1.92
▼
$2.04
50-Day Range
$1.73
▼
$2.42
52-Week Range
$1.24
▼
$4.47
Volume
118,956 shs
Average Volume
131,781 shs
Market Capitalization
$251.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

VAXX stock logo

About Vaxxinity (NASDAQ:VAXX) Stock

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.

Receive VAXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter.

VAXX Stock News Headlines

May 14, 2023 | americanbankingnews.com
Vaxxinity (NASDAQ:VAXX) Stock Price Down 7%
May 9, 2023 | finance.yahoo.com
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update
June 9, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
May 3, 2023 | finance.yahoo.com
Vaxxinity, Inc.'s (NASDAQ:VAXX) biggest owners are private companies who got richer after stock soared 23% last week
April 24, 2023 | finance.yahoo.com
Weekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro Recap
April 1, 2023 | americanbankingnews.com
FY2023 EPS Estimates for Vaxxinity, Inc. Cut by Jefferies Financial Group (NASDAQ:VAXX)
March 29, 2023 | americanbankingnews.com
Analysts Offer Predictions for Vaxxinity, Inc.'s Q1 2023 Earnings (NASDAQ:VAXX)
March 28, 2023 | finance.yahoo.com
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
June 9, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
March 28, 2023 | americanbankingnews.com
Vaxxinity (NASDAQ:VAXX) Issues Quarterly Earnings Results
March 27, 2023 | finance.yahoo.com
Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates
March 21, 2023 | finance.yahoo.com
Vaxxinity Joins TransCelerate Research and Development Consortium
March 20, 2023 | finance.yahoo.com
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
March 2, 2023 | finance.yahoo.com
Vaxxinity to Present at Upcoming March Scientific and Medical Conferences
February 24, 2023 | markets.businessinsider.com
Nektar Therapeutics (NKTR) was downgraded to a Sell Rating at Jefferies
January 19, 2023 | finance.yahoo.com
Why Shares of Vaxxinity Jumped This Week
January 5, 2023 | finance.yahoo.com
Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference
December 31, 2022 | finance.yahoo.com
Estimating The Fair Value Of Vaxxinity, Inc. (NASDAQ:VAXX)
December 2, 2022 | finance.yahoo.com
Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612
November 10, 2022 | finance.yahoo.com
Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 3, 2022 | finance.yahoo.com
Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022
November 1, 2022 | finance.yahoo.com
Vaxxinity to Present at Upcoming Investor Conferences in November
October 30, 2022 | finance.yahoo.com
Vaxxinity, Inc. (NASDAQ:VAXX) stock most popular amongst private companies who own 48%, while individual investors hold 21%
October 24, 2022 | finance.yahoo.com
Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia
October 11, 2022 | uk.finance.yahoo.com
Vaxxinity, Inc. (VAXX)
October 3, 2022 | dallasnews.com
UNT Health Science Center gets $150 million for massive Alzheimer’s study - The Dallas Morning News
September 21, 2022 | finance.yahoo.com
Immunis Welcomes Dr. Peter Diamandis to the Executive Advisory Board - Yahoo Finance
See More Headlines

VAXX Price History

VAXX Company Calendar

Last Earnings
3/27/2023
Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VAXX
CUSIP
N/A
CIK
1851657
Web
www.vaxxinity.com
Phone
254-244-5739
Fax
N/A
Employees
87
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.60)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-75,220,000.00
Net Margins
N/A
Pretax Margin
-603,670.63%
Return on Equity
-105.46%
Return on Assets
-66.73%

Debt

Debt-to-Equity Ratio
0.28
Current Ratio
2.77
Quick Ratio
2.77

Sales & Book Value

Annual Sales
$70,000.00
Price / Sales
3,597.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.49 per share
Price / Book
4.06

Miscellaneous

Outstanding Shares
126,540,000
Free Float
51,793,000
Market Cap
$251.81 million
Optionable
Not Optionable
Beta
2.71

Key Executives

  • Mr. Louis Garfield Reese IV (Age 41)
    Co-Founder & Exec. Chairman
    Comp: $83.28k
  • Ms. Mei Mei Hu J.D. (Age 40)
    CEO & Director
    Comp: $551.73k
  • Mr. Rene Paula Molina J.D. (Age 45)
    Sr. VP of Legal & Bus. Affairs, Gen. Counsel & Sec.
    Comp: $480.13k
  • Dr. Ulo Palm M.D. (Age 66)
    Ph.D., Chief Medical Officer
    Comp: $585k
  • Mr. Jason Pesile CPA (Age 50)
    M.B.A., Sr. VP of Fin. & Accounting
  • Mr. Dwayne Soisson
    VP of Operations
  • Mr. Jon Harrison
    Chief Gov. Officer
  • Mr. Mark Joinnides
    Chief of Staff
  • Ms. Amy B. Fix M.B.A.
    M.S., R.A.C., Chief Regulatory Officer
  • Dr. Jean-Cosme Dodart Ph.D.
    Sr. VP of Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VAXX Stock - Frequently Asked Questions

How have VAXX shares performed in 2023?

Vaxxinity's stock was trading at $1.40 on January 1st, 2023. Since then, VAXX shares have increased by 42.1% and is now trading at $1.99.
View the best growth stocks for 2023 here.

When is Vaxxinity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our VAXX earnings forecast.

How were Vaxxinity's earnings last quarter?

Vaxxinity, Inc. (NASDAQ:VAXX) posted its quarterly earnings data on Monday, March, 27th. The company reported ($0.16) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.16).

What ETF holds Vaxxinity's stock ?

ETFMG Treatments Testing and Advancements ETF holds 43,836 shares of VAXX stock, representing 0.52% of its portfolio.

When did Vaxxinity IPO?

(VAXX) raised $90 million in an initial public offering on Thursday, November 11th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share.

What is Vaxxinity's stock symbol?

Vaxxinity trades on the NASDAQ under the ticker symbol "VAXX."

Who are Vaxxinity's major shareholders?

Vaxxinity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.30%), Bank of America Corp DE (0.25%), Susquehanna International Group LLP (0.24%), State Street Corp (0.10%), HRT Financial LP (0.05%) and Squarepoint Ops LLC (0.04%). Insiders that own company stock include Lou Reese, Mei Mei Hu, Movers Lab Fund I Lp Prime and United Biomedical Inc.
View institutional ownership trends.

How do I buy shares of Vaxxinity?

Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxxinity's stock price today?

One share of VAXX stock can currently be purchased for approximately $1.99.

How much money does Vaxxinity make?

Vaxxinity (NASDAQ:VAXX) has a market capitalization of $251.81 million and generates $70,000.00 in revenue each year. The company earns $-75,220,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

How can I contact Vaxxinity?

The official website for the company is www.vaxxinity.com. The company can be reached via phone at 254-244-5739 or via email at ir@vaxxinity.com.

This page (NASDAQ:VAXX) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -